Navigation Links
Ambiguity In Patent Laws May Defer New Drug Launches

Indian Government has refused to grant product patent for Glivec, the cancer drug from Novartis AG, the Swiss pharma giant. As a result Novartis may not be able to conduct// their drug research here in India. Singapore and China are the countries where Novartis conducts its research now.

While talking on this issue, Paul Herrling, who heads Corporate Research division of Novartis reveals that this decision by the Indian government could hamper the launch of their patented products. But this in any way will not affect the distribution of Glivec here. According to him, Novartis through its foundation has been distributing Glivec to needy patients to the tune of 1270 crore in India.

Trade analysts opine that if such drugs are not available freely in the market and are being prescribed by the physicians and supplied by a few pharmacies, it would prove to be very expensive to the patients.

Herrling feels that the primary objective of any drug company should be to improve health care services. They should focus their research on this area. Product patent alone is not sufficient but data individuality is more important.
JYT
'"/>




Page: 1

Related medicine news :

1. Botched Abortions Trigger Concern Over Legal Ambiguity In Britain
2. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
3. HIV Patients Opposes Patenting Of AIDS Drug
4. Provigil Patent Extension Accorded To Cephalon
5. AIDS Sufferers Protest against Proposed Patent for Tenofovir
6. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
7. Venus Remedies Files 5th International Patent Application
8. US Court Rules Against Lupin in Ramipril Patent Case
9. Patent for Seminal RNAi innovation Cleared in Australia
10. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
11. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: